Cellectis Stock

Cellectis EV/EBIT

Delisted·Jun 19, 2026

The EV/EBIT (Enterprise Value to EBIT) of Cellectis (ALCLS.PA) as of Aug 12, 2026 is -4.76. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -2.91 — a change of 63.38% (lower).

EV/EBIT

-4.76

YoY

63.38%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Cellectis is 2026 -4.76 . EV/EBIT (Enterprise Value to EBIT) of Cellectis was 2025 -2.91 . It decreases by 63.38% lower compared to the previous year.

The Cellectis EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
0.00 base
Jan 1, 2020
-28.77 base
Jan 1, 2021
-3.78 base
Jan 1, 2022
-1.18 base
Jan 1, 2023
-1.90 base
Jan 1, 2024
-2.91 base
Jan 1, 2025 (e)
-6.72 base
Jan 1, 2026 (e)
-5.69 base
YEARPRICE-TO-EBIT
2026 est -5.69
2025 est -6.72
2024 -2.91
2023 -1.90
2022 -1.18
2021 -3.78
2020 -28.77
2019 -
2018 -
2017 -
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
2006 -
2005 -
Access this data via the Eulerpool API

Cellectis Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Cellectis's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Cellectis's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Cellectis's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Cellectis grows earnings faster than its peers.

Cellectis Stock analysis

What does Cellectis do? Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellectis stock

EV/EBIT (Enterprise Value to EBIT) of Cellectis is -4.76 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Cellectis changed from -2.91 to -4.76, representing a 63.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Cellectis since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Cellectis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Cellectis

All Key Metrics — Cellectis